BioSpace News Archive

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, presented posters on two data sets from the Company’s Phase 3 VANISH Program demonstrating the therapeutic potential of ibrexafungerp (Brexafemme) as a treatment for vulvovaginal candidiasis (VVC

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the European Commission (EC) has approved oral, once-daily ORLADEYO™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older.

Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards (“IFRS”).

During the webcast, Michael McFadden, Chief Executive Officer, will provide a presentation that will cover key areas of Alpha Cognition’s business.

KCAS Bioanalytical and Biomarker Services, a laboratory services focused contract research organization is pleased to announce the addition of.

Midatech Pharma PLC (AIM:MTPH.L); (NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces its audited preliminary results for the year ended 31 December 2020.

The financial report is posted on SEDAR. Paul Blunden, M.D., President CVR Medical Corp., acknowledges the quality work put in by the Audit Committee to complete the 2020 Audit in timely manner.

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting on May 5-6, 2021, at the annual Outsourcing in Clinical Trials Europe. The 11th edition of the event will be hosted virtually this year, inviting hundreds of industry leaders to network with peers and share their success stories.

Cloud DX a leading Canadian provider of virtual care and remote patient monitoring solutions is pleased to announce that, subject to regulatory approval, it has retained Red Cloud Securities to initiate its market making service to provide market making services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange and other applicable legislation.